Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials.
作者信息
Hsueh Chung-Tsen, Liu Delong, Wang Hong
机构信息
New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA.
出版信息
Biomark Res. 2013 Jan 16;1(1):1. doi: 10.1186/2050-7771-1-1.
Abstract
摘要
相似文献
1
Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials.用于诊断、预后、靶向治疗及临床试验的新型生物标志物。
Biomark Res. 2013 Jan 16;1(1):1. doi: 10.1186/2050-7771-1-1.
2
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL.慢性淋巴细胞白血病靶向治疗时代预后因素的相关性
Curr Hematol Malig Rep. 2019 Aug;14(4):302-309. doi: 10.1007/s11899-019-00511-1.
3
Novel biomarkers for the diagnosis and prognosis of gallbladder cancer.用于胆囊癌诊断和预后的新型生物标志物。
J Dig Dis. 2021 Feb;22(2):62-71. doi: 10.1111/1751-2980.12966.
4
Integrating biomarkers in clinical trials.将生物标志物纳入临床试验。
Expert Rev Mol Diagn. 2011 Mar;11(2):171-82. doi: 10.1586/erm.10.120.
5
Molecular pathways and potential biomarkers in gallbladder cancer: A comprehensive review.胆囊癌中的分子通路和潜在生物标志物：全面综述。
Surg Oncol. 2019 Dec;31:83-89. doi: 10.1016/j.suronc.2019.09.006. Epub 2019 Sep 13.
6
Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.利用基因表达和癌症生物标志物为个性化医疗时代铺平道路。
Genomics Proteomics Bioinformatics. 2017 Aug;15(4):220-235. doi: 10.1016/j.gpb.2016.11.005. Epub 2017 Aug 13.
7
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma.血管内皮生长因子靶向治疗肾细胞癌的预测和预后生物标志物的系统评价。
Cancer Treat Rev. 2014 May;40(4):533-47. doi: 10.1016/j.ctrv.2013.11.008. Epub 2013 Dec 4.
8
Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia.将分子生物标志物纳入慢性淋巴细胞白血病的连续护理中。
Leuk Lymphoma. 2021 Jun;62(6):1289-1301. doi: 10.1080/10428194.2020.1869966. Epub 2021 Jan 7.
9
Targeting claudins in cancer: diagnosis, prognosis and therapy.靶向紧密连接蛋白治疗癌症：诊断、预后与治疗
Am J Cancer Res. 2021 Jul 15;11(7):3406-3424. eCollection 2021.
10
Current and emerging biomarkers in tumors of the central nervous system: Possible diagnostic, prognostic and therapeutic applications.中枢神经系统肿瘤的现有和新兴生物标志物：可能的诊断、预后和治疗应用。
Semin Cancer Biol. 2018 Oct;52(Pt 1):85-102. doi: 10.1016/j.semcancer.2017.07.004. Epub 2017 Jul 31.
引用本文的文献
1
Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies.罕见肿瘤的综合基因组分析：靶向治疗之路
Front Oncol. 2020 Apr 21;10:536. doi: 10.3389/fonc.2020.00536. eCollection 2020.
2
A new role of C-Choline PET in localizing the epileptogenic foci in insular cortex in the patients.C-胆碱PET在定位患者岛叶皮质癫痫病灶中的新作用。
CNS Neurosci Ther. 2020 Jan;26(1):144-147. doi: 10.1111/cns.13215. Epub 2019 Sep 11.
3
Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis.用于了解阿尔茨海默病发病机制多个方面的脑脊液生物标志物。
Cell Mol Life Sci. 2019 May;76(10):1833-1863. doi: 10.1007/s00018-019-03040-5. Epub 2019 Feb 15.
4
Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors.3-芳基吲唑类化合物的合成及作为选择性 MEK4 抑制剂的生物评价。
ChemMedChem. 2019 Mar 22;14(6):615-620. doi: 10.1002/cmdc.201900019. Epub 2019 Feb 19.
5
Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.选择性MEK1/2抑制剂匹美替尼的药理学
Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):373-382. doi: 10.1007/s13318-018-0466-x.
6
A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data.对从与行政索赔数据直接整合的新型癌症护理质量项目中获取的临床数据进行验证。
Pragmat Obs Res. 2017 Aug 26;8:149-155. doi: 10.2147/POR.S140579. eCollection 2017.
7
A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.一种用于探究MEK激酶家族抑制剂选择性的化学探针策略。
ACS Chem Biol. 2017 May 19;12(5):1245-1256. doi: 10.1021/acschembio.6b01060. Epub 2017 Mar 20.
8
B-Raf and the inhibitors: from bench to bedside.B-Raf 与抑制剂：从实验室到临床。
J Hematol Oncol. 2013 Apr 25;6:30. doi: 10.1186/1756-8722-6-30.
9
MEK and the inhibitors: from bench to bedside.MEK 抑制剂：从实验室到临床。
J Hematol Oncol. 2013 Apr 12;6:27. doi: 10.1186/1756-8722-6-27.
本文引用的文献
1
Current management and prognostic features for gastrointestinal stromal tumor (GIST).胃肠道间质瘤（GIST）的当前治疗管理和预后特征。
Exp Hematol Oncol. 2012 Jun 18;1(1):14. doi: 10.1186/2162-3619-1-14.
2
Recent advances and novel agents for gastrointestinal stromal tumor (GIST).胃肠道间质瘤（GIST）的最新进展和新型药物。
J Hematol Oncol. 2012 May 8;5:21. doi: 10.1186/1756-8722-5-21.
3
Current management and novel agents for malignant melanoma.恶性黑素瘤的当前治疗方法和新型药物。
J Hematol Oncol. 2012 Feb 14;5:3. doi: 10.1186/1756-8722-5-3.
4
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.BRAF V600E 突变型黑色素瘤患者采用威罗菲尼治疗后生存改善。
N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5.
5
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.尼洛替尼与伊马替尼用于治疗新诊断的慢性髓性白血病。
N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.
Zotero 插件